Onesource Specialty Pharma Limited, a active public limited company, was established on 12 June 2007 in Thane, Maharashtra, India. Engaging in chemical products within the manufacturing sector, it holds CIN: L74140MH2007PLC432497. Registered under ROC Roc Mumbai. it is listed. It has an authorized capital of ₹15.00 Cr and a paid-up capital of ₹11.46 Cr.
Formerly known as Inbiopro Solutions Private Limited, Stelis Biopharma Private Limited. It upholds a compliant status. In 2024, it reported revenue of ₹176.14 Cr and a net worth of ₹397.74 Cr. Employing 556 professional, Its leadership includes Bharat Dhirajlal Shah (Director), Rashmi Harshadrai Barbhaiya (Director), Neeraj Sharma (Managing Director). Past directors included Mohana Kumar Pillai, Joe Thomas Mangalam, Venkataraman Subramanian Iyer. It holds ₹1,612.02 Cr open charges and ₹1,269.82 Cr settled loans. Its latest AGM occurred on 23 August 2024, with the balance sheet filed on 31 March 2024. It is based at Unit No. 902, Cyber One, Plot No - 4 & 6, Sector 30A, Vashi, Navi Mumbai, Thane, Maharashtra, 400703.
L74140MH2007PLC432497
432497
12 June 2007
₹15.00 Cr
₹11.46 Cr
Roc Mumbai
Listed
Active
Explore comprehensive insights into Onesource Specialty Pharma Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Bharat Dhirajlal Shah | Director | 26 Jul 2024 | Current |
| Rashmi Harshadrai Barbhaiya | Director | 17 May 2024 | Current |
| Neeraj Sharma | Managing Director | 01 Mar 2024 | Current |
| Claudio Dr Albrecht | Additional Director | 27 Feb 2025 | Current |
| Debarati Sen | Additional Director | 27 Feb 2025 | Current |
| Arun Kumar Pillai | Director | 07 Apr 2021 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Director | 09 Jul 2018 | Past |
| Pramod Abcsdd | Whole-Time Director | 31 Jan 2020 | Past |
| Pramod Abcsdd | Additional Director | 08 Aug 2017 | Past |
| Pramod Abcsdd | Director | 18 Nov 2010 | Past |
| Pramod Abcsdd | Nominee Director | 18 Mar 2013 | Past |
| Pramod Abcsdd | Additional Director | 22 Aug 2024 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Onesource Specialty Pharma Limited, for the financial year ended 2024, experienced significant growth in revenue, with a 285% increase. The company also saw a substantial improvement in profitability, with a 51.15% increase in profit. The company's net worth observed a substantial decline by a decrease of 49.44%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2024, Onesource Specialty Pharma had a promoter holding of 30.29% and a public holding of 69.71%. The company had 1 Subsidiary. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹16,120,200,000.00
₹12,698,159,503.00
| Date | Lender | Amount | Status |
|---|---|---|---|
| 25 Sep 2025 | Others | ₹150.00 Cr | Open |
| 22 Sep 2025 | Others | ₹100.00 Cr | Open |
| 29 Aug 2025 | Standard Chartered Bank | ₹125.00 Cr | Open |
| 19 Jun 2025 | Yes Bank Limited | ₹50.00 Cr | Open |
| 25 Apr 2025 | Others | ₹150.00 Cr | Open |
Explore comprehensive loan charge details -
Onesource Specialty Pharma has a workforce of 556 employees as of Mar 10, 2025. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Onesource Specialty Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Onesource Specialty Pharma's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Progress on A charge with Others amounted to Rs. 150.00 Cr with Charge ID 101167111 was registered on 25 Sep 2025. was documented.
Progress on A charge with Hdfc Bank Limited of Rs. 146.00 Cr registered on 28 Feb 2025 with Charge ID 101080678 was modified on 23 Sep 2025. was documented.
The activity A charge with Others amounted to Rs. 100.00 Cr with Charge ID 101167815 was registered on 22 Sep 2025. was completed.
A charge with Standard Chartered Bank amounted to Rs. 125.00 Cr with Charge ID 101157658 was registered on 29 Aug 2025. was recorded as a recent event.
Progress on Colin Bond Michael was appointed as a Director was appointed as a Director on 23 Jun 2025 & has been associated with this company since 5 months 10 days . was documented.
A charge with Yes Bank Limited amounted to Rs. 50.00 Cr with Charge ID 101113934 was registered on 19 Jun 2025. was recorded as a recent event.
To add 20,000 litres of installed biologics drug substance manufacturing capacity Syngene announced the acquisition of Unit 3 biologics manufacturing facility in Bengaluru, from Stelis Biopharma Limit.
Strides Pharma Science invests more money in Stelis Biopharma to take control. They already put in $35 million for 43% ownership. Now, they'll add up to $40 million in 2 years to become a big player in biopharmaceuticals and get back into sterile injectables. Stelis will break even in 18 months with help from other partners. Stelis has a research facility in Bengaluru and makes biosimilars. Strides Pharma shares went up 0.18%..
The company's board has approved participation in the Series B fundraiser of Stelis Biopharma with a commitment of USD 15 million, Strides Pharma Science said in a regulatory filing. .
The CIN of Onesource Specialty Pharma Limited is L74140MH2007PLC432497.
Onesource Specialty Pharma Limited is headquartered at Unit No. 902, Cyber One, Plot No - 4 & 6, Sector 30A, Vashi, Navi Mumbai, Thane, Maharashtra, 400703.
Onesource Specialty Pharma Limited was incorporated on 12 June 2007.
The current directors of Onesource Specialty Pharma Limited are
The primary industry of Onesource Specialty Pharma Limited is Manufacturing.
Onesource Specialty Pharma Limited is listed.
The authorized capital of Onesource Specialty Pharma Limited is ₹15.00 Cr, and the paid-up capital is ₹11.46 Cr.
The compliance status of Onesource Specialty Pharma Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX